EIKCS 2022: Relevance of Items in the FACT Kidney Cancer Symptom Inventory-19 (FKSI-19): Results of a Patient Survey urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
Eisai to Present Investigational Data on LENVIMA® (lenvatinib) Based Combination Therapies in Renal Cell Carcinoma at the 2021 Genitourinary Cancers Symposium
Data include the first presentation of results from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA and LENVIMA plus everolimus
News provided by
Share this article
Share this article
WOODCLIFF LAKE, N.J., Jan. 27, 2021 /PRNewswire/ Eisai will present four abstracts at the virtual Genitourinary Cancers Symposium 2021 (#GU21) from February 11-13, 2021. These investigational data include a late-breaking oral presentation from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) (NCT02811861) (Abstract # 269) evaluating KEYTRUDA plus LENVIMA and LENVIMA plus everolimus versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC).